glp-1 cardiovascular outcomes 2025 news of semaglutide and tirzepatide for patients with type 2 diabetes in clinical practice Prioritizing Health | Diabetes, Diet

You may have seen reports of Trulicity being used for weight loss

They undergo rigorous testing for safety, efficacy, and manufacturing consistency

Asia-Pacific: The Fastest-Growing Region Asia-Pacific held a 15% share of the GLP-1 market in 2025 and is expected to grow at the fastest CAGR of 18.2% during the projection period, driven by a growing diabetic population and rising obesity prevalence

However, we also have a constant, low level of circulating GLP-1 even when fasting.[ref][ref] This directly ties into the gut microbiome

demonstrated that GLP-1RAs, such as semaglutide, confer protective effects in polymicrobial sepsis by activating neuronal GLP-1R